Apelin-potential therapy for COVID-19?

We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeedi Saravi, Seyed Soheil, Beer, Jürg H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299869/
https://www.ncbi.nlm.nih.gov/pubmed/32562701
http://dx.doi.org/10.1016/j.yjmcc.2020.06.007
_version_ 1783547458344714240
author Saeedi Saravi, Seyed Soheil
Beer, Jürg H.
author_facet Saeedi Saravi, Seyed Soheil
Beer, Jürg H.
author_sort Saeedi Saravi, Seyed Soheil
collection PubMed
description We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1–7) ratio.
format Online
Article
Text
id pubmed-7299869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72998692020-06-18 Apelin-potential therapy for COVID-19? Saeedi Saravi, Seyed Soheil Beer, Jürg H. J Mol Cell Cardiol Article We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1–7) ratio. Elsevier Ltd. 2020-08 2020-06-18 /pmc/articles/PMC7299869/ /pubmed/32562701 http://dx.doi.org/10.1016/j.yjmcc.2020.06.007 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Saeedi Saravi, Seyed Soheil
Beer, Jürg H.
Apelin-potential therapy for COVID-19?
title Apelin-potential therapy for COVID-19?
title_full Apelin-potential therapy for COVID-19?
title_fullStr Apelin-potential therapy for COVID-19?
title_full_unstemmed Apelin-potential therapy for COVID-19?
title_short Apelin-potential therapy for COVID-19?
title_sort apelin-potential therapy for covid-19?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299869/
https://www.ncbi.nlm.nih.gov/pubmed/32562701
http://dx.doi.org/10.1016/j.yjmcc.2020.06.007
work_keys_str_mv AT saeedisaraviseyedsoheil apelinpotentialtherapyforcovid19
AT beerjurgh apelinpotentialtherapyforcovid19

Ejemplares similares